Trial Profile
A Randomized, Open-Label, Multicenter, Phase 2 Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors Janssen-Cilag; Millennium
- 11 Jun 2013 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 11 Jun 2013 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 25 Feb 2012 Additional locations (Argentina,Australia, Brazil, Canada,South Korea, Malaysia, Mexico, Russia, Singapore, Turkey) added as reported by European Clinical Trials Database.